TD Private Client Wealth LLC Increases Holdings in Cencora, Inc. (NYSE:COR)

TD Private Client Wealth LLC grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 8.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,989 shares of the company’s stock after buying an additional 541 shares during the period. TD Private Client Wealth LLC’s holdings in Cencora were worth $1,573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. Neo Ivy Capital Management purchased a new stake in Cencora during the 3rd quarter worth about $3,916,000. Coldstream Capital Management Inc. lifted its holdings in Cencora by 11.0% during the 3rd quarter. Coldstream Capital Management Inc. now owns 3,299 shares of the company’s stock worth $750,000 after buying an additional 328 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Cencora by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company’s stock worth $941,183,000 after buying an additional 189,054 shares during the last quarter. Vestcor Inc lifted its holdings in Cencora by 13.1% during the 3rd quarter. Vestcor Inc now owns 3,438 shares of the company’s stock worth $774,000 after buying an additional 398 shares during the last quarter. Finally, Continuum Advisory LLC lifted its holdings in Cencora by 8.2% during the 3rd quarter. Continuum Advisory LLC now owns 1,084 shares of the company’s stock worth $264,000 after buying an additional 82 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 93,018 shares of company stock valued at $22,478,942. Corporate insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on COR shares. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI upped their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Mizuho started coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $276.80.

Cencora Stock Up 0.1 %

COR opened at $232.16 on Friday. The business has a 50 day moving average price of $238.11 and a two-hundred day moving average price of $233.82. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a market cap of $44.87 billion, a PE ratio of 30.91, a P/E/G ratio of 1.62 and a beta of 0.45. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $253.27.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.95%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.